Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In order to explore the binding sites for calcium-activated neutral protease (CANP) with high calcium sensitivity (
muCANP
) on the inner surface of human erythrocyte membranes, we analyzed the binding of
muCANP
to two kinds of membranes modified by treatment with
phospholipase C
or Triton X-100. Binding analyses were performed using an immunoblot technique. The amount of
muCANP
bound to
phospholipase C
-treated inside-out vesicles was essentially the same as that bound to untreated inside-out vesicles. It was also observed that
muCANP
binds to Triton X-100-treated membranes, in which most of the integral proteins and glycerophospholipids are removed while the lining proteins remain intact. In both types of modified membrane, the bound
muCANP
was rapdily converted to an active form by autolysis at physiological free Ca2+ concentrations. These results indicate that the binding sites for
muCANP
on the inner surface of erythrocyte membranes consist of components other than membrane phospholipids. In addition, it is suggested that one of the binding sites for
muCANP
is some lining protein.
...
PMID:Binding sites for calcium-activated neutral protease on erythrocyte membranes are not membrane phospholipids. 240 52
